A Phase 2b/3 Study to Evaluate the Safety, Tolerability, and Effects of Livoletide (AZP-531), an Unacylated Ghrelin Analogue, on Food-related Behaviors in Patients With Prader-Willi Syndrome
This Phase 2b/3 double-blind, placebo-controlled study will evaluate the safety, tolerability, and effects of livoletide on food-related behaviors in patients with Prader-Willi Syndrome (PWS).
100 项与 Millendo Therapeutics SAS 相关的临床结果
0 项与 Millendo Therapeutics SAS 相关的专利(医药)
100 项与 Millendo Therapeutics SAS 相关的药物交易
100 项与 Millendo Therapeutics SAS 相关的转化医学